Business Wire

Cellestia Biotech AG successfully closes Series B financing round, raising a total of CHF 20 million

Share
  • Financing round led by FC Capital, Shanghai; PPF Group; Partners Investment, Seoul; and significant investments by existing and new private investors.
  • Funds will be used to finance the operations and to advance the ongoing Phase l clinical trial into Phase II.
  • Guido Guidi and Robert Karsunky elected to Cellestia’s Board of Directors.

Cellestia Biotech AG today announced the closing of a CHF 20 million Series B financing round. The new funds will be added to the previous, including CHF 8 million Seed financing, CHF 20 million Series A financing and CHF 1 million non-dilutive research grants, bringing the total capital raised to date by Cellestia to CHF 49 million (USD 50 million).

“This financing strengthens our balance sheet as we work to achieve important milestones for our clinical candidate CB-103 as well as the follow-up compounds,” said Gaudenz von Capeller, CFO of Cellestia Biotech AG.

Cellestia is progressing the ongoing clinical development program of CB-103, a first-in-class small molecule targeted therapy with a novel mode of action. CB-103 is a highly selective protein-protein interaction inhibitor targeting an oncogene transcription factor for the precision medicine treatment of specific cancers. It will also allow Cellestia to advance its innovative R&D pipeline activity.

In June 2019, Guido Guidi (Former Head Europe Novartis Pharma / Head Novartis Oncology Europe) was elected new Chairman of Board of Directors. Robert Karsunky (Head Latin America & Canada at Novartis Pharma) elected new Chairman of the Audit Committee and to the Board of Directors.

Michael Bauer, CEO of Cellestia Biotech AG said, “Guido’s experience and knowledge in development, business and building a successful organisation is a tremendous asset to our company, and we are delighted that he has joined Cellestia as Chairman of our Board. Robert brings long-standing financial expertise to the board and strengthens internal governance in his roles of Chairman of the Audit Committee and Member of the Board. With these additions to the board, we are further adopting the board memberships in line with the company´s growth and development.”

“I am excited to be a part of Cellestia’s journey. I find the science to be compelling and look forward to supporting the development of this novel precision oncology solution,” said Guido Guidi.

About PPF/SOTIO

PPF Group is an international investment company focusing on multiple market segments such as banking, financial services, telecommunications, insurance, real estate, agriculture and biotechnology. PPF’s reach spans from Europe to Russia, the USA and across Asia. PPF's assets under management totalled to almost EUR 47 billion (as at 30 June 2019). SOTIO is an international biotechnology company spearheading PPF’s investment and partnering activities in the biotechnology sector. For more information about PPF and Sotio visit www.ppf.eu and www.sotio.com.

About FC Capital

FC Capital is a China-based private equity firm specializing in healthcare investments in the Greater China region, the US and the European countries. FC Capital focuses in cultivating and investing in early and growth stage sector leaders ranging from pharmaceutical companies to technology and data providers that are aligning with secular growth trends or building innovative solutions to emerging challenges. Its parallel RMB and USD funds target high-quality companies looking for a patient and strategic partner to achieve unprecedented cross-border and long-term success.

About Partners Investment

Partners Investment Co., Ltd. is a private equity and venture capital firm from the Republic of Korea, specializing in investments in buyouts and start-up companies. The firm typically invests in the Information technology, biotechnology, digital contents, machinery, materials, video, information and communication, healthcare, electronics, internet/game, and medical devices sectors. Partners Venture Capital Co., Ltd. was founded in 2000 and is based in Seoul, South Korea. Visit www.partnersi.co.kr.

About Cellestia Biotech AG

Cellestia is a clinical-stage biopharma company targeting cancer at a level of gene transcription. The clinical candidate of Cellestia is CB-103, a novel, first-in-class oral pan-NOTCH inhibitor indicated for treatment of patients with NOTCH-driven leukemias, lymphomas and solid tumors. CB-103 is the first drug to selectively target this pathway at the level of the oncogenic transcription factor. Cellestia holds a worldwide exclusive license on the intellectual property rights for CB-103 and related series of analogues, for development and commercialization. The company pursues an integrated approach combining drug and personalized medicine development for patient selection.

Webpage: https://www.cellestia.com/

www.cellestia.com

Contact information

Cellestia Biotech AG
Media Enquiries

Dr. Michael Bauer, CEO
+41 61 633 29 80
michael.bauer@cellestia.com

Gaudenz von Capeller, CFO
+41 79 798 64 43
gaudenz.voncapeller@cellestia.com

Mathilde Claire Vincent, Head of Communication
+41 79 591 57 23
mathilde.vincent@cellestia.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells3.8.2020 20:03:00 EESTPress release

NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) “Relief” today announced that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19. At the same time, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes. RLF-100 has been granted Fast Track designation by FDA and is being developed as a Material Threat Medical Countermeasure in cooperation with the National Institutes of Health and other federal agencies. Further research will be conducted. The first report of rapid clinical recovery under emergency use IND was posted by doctors from Houston Methodist Hospital. The report describes a 54-year-old man who developed COVID-19 while being treated for rejection of a double lung transplant and who came off a ventilator within four days.1 Similar results were subsequently seen in more than 15 patients treated under emergency use IND

Panasonic Corporation announces verification of inhibitory effect of hydroxyl radicals contained in water (nano-sized electrostatic atomized water particle) on novel coronavirus (SARS-CoV-2)3.8.2020 18:47:00 EESTPress release

Panasonic Corporation today announced that, in collaboration with Mayo Yasugi, Associate Professor, Department of Veterinary Science, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, it has verified the inhibitory effect of the hydroxyl radicals contained in water (nano-sized electrostatic atomized water particle) on the novel coronavirus (SARS-CoV-2). Hydroxyl radicals contained in water are particulate ions containing hydroxyl radicals that are generated by applying a high voltage to moisture in the air. They are characterized by being strongly oxidative and highly reactive. Panasonic has been conducting research on this technology over the past 20 years since 1997, and has verified its effectiveness in a variety of areas, including inhibiting pathogenic microorganism (bacteria, fungi, and viruses) and allergens, breaking down PM 2.5 components that have adverse effects on the human body*1. In 2012, Panasonic conducted a virus clearance test with a thi

OpenGate Capital Strengthens Management Team with Tenured Chief Financial Officer3.8.2020 17:43:00 EESTPress release

OpenGate Capital, a global private equity firm, announced today that their senior leadership team has expanded with the addition of Heather Malloy who joined the firm today as Chief Financial Officer based in the firm’s Los Angeles office. Malloy is a tenured, private equity finance executive with an extensive background in corporate strategy, structuring, and systems. She is experienced in control buyouts, senior, junior, and mezzanine debt, structured finance, and asset-backed securities. Prior to joining OpenGate, Malloy was a management consultant at Riva Ridge Management, and she previously served as Chief Operating Officer and Chief Financial Officer at Strattam Capital for six years. In her role at OpenGate Capital, Malloy is responsible for the financial and administrative matters of OpenGate Capital, the funds under OpenGate’s management, and the financial supervision of OpenGate’s global portfolio companies. Andrew Nikou, OpenGate’s Founder and Chief Executive Officer stated,

Alpega Partners with project44 to Deliver Advanced Visibility in North America and Europe3.8.2020 17:15:00 EESTPress release

Alpega, a global provider of cloud-based transportation management systems (TMS), today announced as part of its growing value-adding partner ecosystem, it has partnered with project44, a global leader in supply chain visibility for shippers and logistics service providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005311/en/ Alpega Partners with project44 to Deliver Advanced Visibility in North America and Europe (Photo: Business Wire) The partnership delivers real-time truckload tracking integration and serves Alpega customers of all industries and verticals across North America and Europe. “We are happy to join efforts with Alpega to serve our global community of customers,” said Tommy Barnes, Head of Global Network Partnerships at project44. “We want to enable supply chain professionals all over the world to make informed decisions based on high quality, real-time data, and drive more operational efficiencies

 JEOL: Release of the New Scanning Electron Microscope JSM-IT700HR3.8.2020 17:00:00 EESTPress release

JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new scanning electron microscope (SEM), the JSM-IT700HR for unprecedentedly high throughput in August 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005011/en/ Note: The photo of the instrument is JSM-IT700HR/LA. (Photo: Business Wire) Development background Scanning electron microscopes are used in various fields, such as nanotechnology, metals, semiconductors, ceramics, medicine, and biology. In addition, SEM applications are expanding to include quality control as well as basic research. The demands are increasing for faster data acquisition of higher-quality SEM images and for easier confirmation of compositional information. Based on our award-winning predecessor of “InTouchScope™” series SEMs, the JSM-IT700HR is equipped with our in-lens Schottky field emission electron gun (FEG). This new powerful SEM satisfies the needs for obser

Immervision Orders Investigation by Ad Hoc Research to Clearly See Smartphone Camera Performance from End Users Point of View3.8.2020 16:00:00 EESTPress release

Immervision, the Montreal-based developer and licensor of patented, wide-angle optics and imaging technology, today announced its 2020 Smartphone Camera survey results in cooperation with Ad Hoc Research. Amid confusing end-user comments on photos and videos and disagreement between phone makers on what has to be done, Immervision decided to investigate what end-user like or don’t like from their phone’s cameras. It revealed no smartphone brand, even the flagship brands, is performing well in consumers’ experience in taking photos. The survey included 1,557 consumers located in California, China and South Korea who selected pictures they preferred amongst 10 images for each of the four scenes comprising city landscape and people. Photos were taken on settings from the same angle and under the same environmental conditions. Results were based on region, age, gender. Data was collected February 20 - March 5, 2020. Ad Hoc Research said, “Our study showed that with current functionalities,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom